Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

January 21, 2021January 21, 2021

Potentially Less Toxic Chemo for AML Named Orphan Drug in Europe

News

Aspacytarabine (BST-236), a possibly less toxic form of chemotherapy being developed by Biosight for people with acute myeloid leukemia (AML), has been designated an orphan medicinal product by the European Medicines ... Read more

January 14, 2021January 14, 2021

Canada Approves Onureg, Oral Chemotherapy for AML Patients in Remission

News

Health Canada has approved Onureg, an oral formulation of the chemotherapy azacitidine, as the first maintenance therapy for adults with acute myeloid leukemia (AML) who have achieved complete remission after intensive induction chemotherapy. ... Read more

January 4, 2021January 4, 2021

CPI-613 on FDA Fast Track to Treat AML

News

CPI-613 (devimistat) has been granted a fast track designation by the U.S. Food and Drug Administration to treat acute myeloid leukemia (AML), announced its developer, Rafael Pharmaceuticals. The designation is ... Read more

December 2, 2020December 3, 2020

FDA Puts Eprenetapopt on Fast Track for Treating TP53 Mutant AML

News

Eprenetapopt (APR-246), an investigational therapy being developed by Aprea Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration for treating acute myeloid leukemia (AML) with mutations in the TP53 gene. ... Read more

November 16, 2020November 16, 2020

US Trial Testing Mylotarg Plus Venclexta for AML Now Enrolling Participants

News

A Phase 1b study testing Mylotarg (gemtuzumab ozogamicin) plus Venclexta (venetoclax) for adults with relapsing or refractory acute myeloid leukemia (AML) is currently enrolling patients. The trial (NCT04070768) is taking place across four clinical sites ... Read more

October 29, 2020October 29, 2020

Dosing Begins in Phase 1 Trial Testing PRT1419 for Advanced AML, Other Blood Cancers

News

The first patient has been dosed in a Phase 1 trial testing the investigational cancer therapy PRT1419 in patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML), Prelude ... Read more

September 24, 2020September 24, 2020

Dosing Begins in Phase 1 Trial Testing Immune-Onc’s IO-202 for Advanced AML, CMML

News

The first patient has been dosed in Immune-Onc Therapeutic’s Phase 1 clinical trial of IO-202, its lead antibody treatment candidate for advanced acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The trial (NCT04372433), underway ... Read more

April 16, 2020April 16, 2020

COVID-19 Pandemic Stops Phase 2 Trial of Ficlatuzumab Combo Therapy for AML

News

The Phase 2 CyFi-2 study assessing the safety and efficacy of ficlatuzumab (previously AV-299) combined with standard chemotherapy in patients with hard-to-treat acute myeloid leukemia (AML) has been discontinued due ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking ... Read more

January 31, 2020February 6, 2020

First AML Patient Dosed in Phase 1 Trial of Cellectis’ CAR T-cell Therapy, UCART123

News

Cellectis has started dosing participants in its Phase 1 trial assessing the safety and clinical activity of an updated version of UCART123, its CAR T-cell therapy for patients with relapsed ... Read more